Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic Concepts by Roger A. Levy et al.
PERSPECTIVE
published: 07 May 2015
doi: 10.3389/fimmu.2015.00205
Edited by:
Luis Eduardo Coelho Andrade,
Universidade Federal de São Paulo,
Brazil
Reviewed by:
Keith Elkon,
University of Washington, USA
Angela Tincani,
University of Brescia and Brescia
Hospital, Italy
*Correspondence:
Roger A. Levy,
Disciplina de Reumatologia, Hospital
Universitário Pedro Ernesto,
Universidade do Estado do Rio de
Janeiro, Blvd 28 de Setembro 77,
Vila Isabel, Rio de Janeiro,
RJ 20551-900, Brazil
rlevy@uerj.br
Specialty section:
This article was submitted to B Cell
Biology, a section of the journal
Frontiers in Immunology
Received: 07 January 2015
Paper pending published:
19 February 2015
Accepted: 14 April 2015
Published: 07 May 2015
Citation:
Levy RA, dos Santos FC, de Jesús
GR and de Jesús NR (2015)
Antiphospholipid antibodies and
antiphospholipid syndrome during
pregnancy: diagnostic concepts.
Front. Immunol. 6:205.
doi: 10.3389/fimmu.2015.00205
Antiphospholipid antibodies and
antiphospholipid syndrome during
pregnancy: diagnostic concepts
Roger A. Levy 1*, Flavia Cunha dos Santos 2, Guilherme R. de Jesús 2 and
Nilson R. de Jesús 2
1 Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2 Department of Obstetrics,
Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Antiphospholipid syndrome (APS) comprises of a wide spectrum of clinical and obstetric
manifestations linked to the presence of antiphospholipid antibodies (aPL). APS was
described in the context of lupus, and later as an isolated syndrome or primary APS.
The presence of aPL, especially the lupus anticoagulant test, is associated with adverse
pregnancy outcomes, such as fetal death, recurrent early miscarriages, pre-eclampsia,
and placental insufficiency, but does not seem to influence infertility. High quality scientific
data to support these associations, however, are lacking, and controversies arise about
the definition of positive aPL (low vs medium-high titers) or even the definition of the
adverse events. This review discusses APS classification criteria and the current debate
about it.
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Background
Antiphospholipid syndrome (APS) involves clinical (venous and arterial thrombosis) and obstetric
manifestations related to the presence of antiphospholipid antibodies (aPL). APS was described in
patients with systemic lupus erythematosus (SLE), and later as an isolated syndrome or primary
APS (PAPS). The classification criteria were designed for the definition of APS to be used by
epidemiologic and clinical studies (1), but are commonlymisused for clinical diagnostic decisions on
an individual basis. According to the APS criteria, obstetrical findings are: one or more unexplained
deaths of a morphologically normal fetus at or beyond the 10th week of gestation, with normal
fetal morphology documented by ultrasound or by direct examination of the fetus; or one or more
premature births of a morphologically normal neonate before the 34th gestational week because
of eclampsia or severe pre-eclampsia according to standard definitions, or recognized features of
placental insufficiency (PI); or three ormore unexplained consecutive spontaneous abortions before
the 10th gestational week; maternal anatomic, hormonal abnormalities, and parental chromosomal
causes excluded (1).
The aPL tests included in the revised criteria for APS classification are: anti-cardiolipin (aCL)
and anti-β2 glycoprotein I (aβ2GPI) antibodies, and the lupus anticoagulant (LA); their presence
should be confirmed at least 12weeks apart. (1). Other autoantibodies directed to proteins involved
in the coagulation cascade or their complex with other phospholipids, or to β2GPI specific domains,
have been proposed to be relevant but their clinical utility and diagnostic value remain unclear.
The clinical relevance of IgA aCL or β2GPI, and if it should be included in the routine diagnostic
algorithm is being discussed (2).
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2051
Levy et al. Diagnostic of APS in pregnancy
The mechanisms of these complications are linked to events
involving several phases of the clotting system, and affecting dif-
ferent vessel sizes and organs. In addition to classical thrombotic
mechanism, causing fetal death due to decidual vessel thrombosis,
aPL have been associated to complement activation, reduction
of annexin-V, and placental tissue damage, ultimately resulting
in abortion (3). These findings are correlated to the pathogenic
mechanism of recurrent early miscarriage (REM), pre-eclampsia,
and PI (4). Other obstetrical complications that can occur during
aPL/APS pregnancy such as fetal growth restriction and fetal
distress do not have a clear thrombotic cause (4).
Recent research suggests that not all aPL confer the same degree
of risk; these findings that may help guide future research and
treatment. Among the aPL, LA is the most powerful predictor
of pregnancy loss. However, aCL and aβ2GPI are also associated
with adverse outcome. Of the aCL isotypes, IgG carries more risk
than IgM, and IgA is not an independent predictor. In addition,
other clinical features, specifically concomitant SLE, contribute to
pregnancy risk. Predictors of events inAPSpatients or aPL carriers
are prior thrombosis history, smoking, and triggering factors such
as surgery, trauma, and severe infections of any kind.
Fetal Death
The relationship between high IgG aCL titers and the chance of
fetal loss is well established, especially if there is a past history
of fetal deaths. A multicenter prospective observational study
reported that LA was the primary predictor of adverse pregnancy
outcome after 12weeks of gestation, including fetal death (5). The
association of fetal death and aPL was the focus of a system-
atic literature review of 2011 (6), and each antibody (LA, aCL,
and aβ2GPI) had positive association. Nevertheless, the authors
highlight several limitations of the studies.
First, the definition of fetal death was heterogeneous, and
several studies included patients with abortion and stillbirth in
the same group of analysis, although an association was found
with both stillbirth (>20weeks of gestation) and fetal death
(>10weeks of gestation). This result suggests that aPL can result
in pregnancy loss during different stages of pregnancy. The other
limitations found were a wide methodological discrepancy in aPL
assays, in the cut-off values applied to the different assays, and
frequently IgG and IgM values were combined. Finally, only a
small number of studies strictly followed the recommendations
of the consensus regarding laboratory tests (1).
The Stillbirth Collaborative Research Network (SCRN) con-
ducted a large, multicenter, multiethnic prospective population-
based study in the US to improve current knowledge considering
the association between aPL and stillbirth (7). Elevated aCL and
aβ2GPI levels were associated with 3- to 5-fold increased odds
of stillbirth in 582 cases of fetal death beyond the 20th week of
gestation. LA, however, was not tested, and longitudinal confir-
mation of the results was not performed to conclude the diagnosis
of APS. Advantages of this study compared to previous ones are
the inclusion of a significant number of cases and the laboratory
centralization for homogeneous testing.
Subsequent qualitative analysis of published studies was per-
formed by the 14th International Congress on Antiphospho-
lipid Antibodies Obstetric Task Force Group (APLA-ObTF),
investigating patients with complete aPL profile. In their literature
review, 10 published studies that performed all the three criteria
tests in women with fetal death were retrieved, and the results
suggest that aPL profile may be important to obstetric APS. Triple
aPL positivity was identified as a risk factor for pregnancy failure
by several studies, and patientswith this aPL profile aremore likely
to have an unequivocal laboratory diagnosis and higher chance to
present the most pathogenic antibodies (8).
There is an ongoing debate about aCL and aβ2GPI titers in
patients with fetal loss, as well with REM. The results of published
studies considering low titers of aPL in pregnancy are conflicting,
ranging from good outcome in almost 80% of cases (9) to poor
obstetric results just like patients with medium-high titers (10).
Other studies, including the SCRN, also described a possible
association between low titer aPL and obstetric events, but a causal
relationship was not confirmed. A different point of view is that
pathologically irrelevant low titer aPL can be found inwomanwith
fetal death.
To alleviate part of these uncertainties, the APLA-ObTF pro-
posed that themost reasonable approach to collect data about aPL-
associated fetal death is through the use of detailed multinational
registries of prospectively followed pregnancies, using centralized
certified laboratories (8). Also, association with aPL profile (triple
vs double vs single positivity) and aPL titer (low vs high titers)
should be investigated in future studies.
Recurrent Early Miscarriages
According to the APS classification criteria (1), three or more
REM are classified, butmany physicians investigate aPL in women
with two early miscarriages. Initially, other identifiable triggers
of REM, which can occur in up to 3% of all fertile women,
must be ruled out. Chromosomal abnormalities in either partner
can account for 4% of the causes, while abnormal embryonic
karyotype in REM has been reported as frequent as in sporadic
abortions (11). The real prevalence – and association – of uterine
malformations, infections, other autoimmune disorders (thyroidi-
tis, celiac disease), and congenital thrombophilias with REM is
not precisely known. APS or aPL can be linked to approximately
15% of the REM, meaning that many times there is no identifiable
cause.
Experimental studies support the association of aPL and REM,
with different proposed mechanisms (3). Several prevalence stud-
ies in the last decades reported a high frequency of aPL in
patients with REM compared to healthy controls (8), but signif-
icant methodological limitations can be found in these papers.
Here again, the importance of using the standardized tests and
follow the rule of considering the cut-off for samples in the
moderate to high range as true positives must be emphasized. The
definition of aPL positivity among studies was unequal and most
did not follow international criteria recommendations (1). Aswith
fetal loss, controversial results have been yielded between low
titers of aPL and REM, and a definite association is not possible.
Also, confirmation of persistent positivity and tests for all three
antibodies were seldom performed, with LA and aCL being more
frequently investigated.
Almost 30% of the studies included in the mentioned literature
review (8) regarding the association of aPL with REM included
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patients with less than three abortions, and a significant number
of the publications did not state if the events were consecutive.
As mentioned before, the inclusion of patients with early losses
(<10weeks) and late abortion or stillbirths in the same group of
analysis could be a confounding factor, since the pathogenesis of
pregnancy loss varies throughout pregnancy. Furthermore, exclu-
sion of other causes of abortion was not clearly stated in these
studies.
With all these limitations, a meta-analysis could only include
two studies (907 patients) to appraise the association between
REM and aPL (12). They found a positive association of aCL
IgG (low and moderate to high titers) and REM before 13weeks’
gestational age, but LA and aCL IgM relationship could not
be evaluated due to lack of studies that followed meta-analysis’
inclusion criteria. The literature review presented during by the
APLA ObTF reported that most studies (27/46) found a pos-
itive association between REM and aPL, but only four papers
strictly followed REM criteria as described in international con-
sensus.
Most publications considering aPL link to REM reported a
positive association, but with a huge heterogeneity that hinders
comparisons. The APLA-ObTF members concluded that multi-
center studies using current international criteria, including stan-
dardized antibodies tests, should be developed to improve our
knowledge about the relationship between aPL and REM.
Well-designed studies should be performed to further under-
stand the association between aPL and two consecutive early abor-
tions, or low titers of aPL with REM. That said, we do not agree
with some recommendations to diagnose patients that do not
fulfill international consensus clinical and/or laboratory criteria
as having “non-criteria obstetric APS” (13), since there is no data
to justify such definition or even their treatment. Further studies
are needed before we can suggest a new diagnostic criteria or an
expansion with new inclusions for the current one.
Pre-Eclampsia and Placental Insufficiency
Most of studies report a positive association between severe, early
onset (prior to 34weeks of gestation) pre-eclempsia (PreE), but
the real frequency is unknown. Two published systematic reviews
supported the association between aPL and PreE (6, 14). One
of them (14) described a positive association between aPL and
severe PreE in pregnant women without autoimmune disease,
but there was no relationship with mild PreE. Both reported
significant heterogeneity of study designs, definition of PreE, and
study size.
Following these reviews, the APLA ObTF group updated the
mentioned systematic analysis with more recent case-control
studies that were published (8). All three antibodies were tested
and only moderate-high titers were considered positive, although
most of studies did not repeat testing to confirm results.
Nevertheless, a positive association was found, especially with
severe PreE.
Considering PI, publications are scarce, the definition is not
well established, even in the obstetric arena, and inclusion cri-
terion varies widely among studies. Most studies analyzing PI
investigate aPL in patients with intrauterine growth restriction
(IUGR), although other features of PI are outlined by theAPS clas-
sification criteria (abnormal or non-reassuring fetal surveillance
test(s), abnormal waveform analysis by Doppler flow suggestive
of fetal hypoxemia and oligohydramnios).
The majority of cohort studies described a positive associa-
tion between aPL and IUGR, but the small number of patients
included and different definitions of IUGR and positive aPL
should be underscored. Also, in fetuses with IUGR, it is difficult to
exclude all confounding factors, including congenital infections,
aneuploidy, or PreE, besides constitutionally small fetuses.
The association between aPL with PreE, especially severe PreE,
and PI seems to be accurate, as both events can occur even with
treated patients with established APS (4). The real frequency of
aPL in these events, nonetheless, remains unknown, considering
all issues previously stated. The most critical flaws of the studies
are related to methodologies applied, and definition of positivity,
heterogeneous definitions of PreE and PI, small sample size, and
lack of repeat testing.
The ObTF proposed that a multicenter study to investigate
aPL prevalence in patients PreE should be performed for a better
understanding of the association. The design of a similar study
considering PI, however, was considered difficult (8).
Infertility
Infertility is not a criterion described in the international con-
sensus (1), but investigation and treatment of aPL in infertile
women is common in clinical practice. As aPL can affect thro-
phoblast invasion and uterine decidualization, it was hypothesized
that those antibodies could act before pregnancy was detected.
However, this theory has never been confirmed.
A critical systematic review of the literature was conducted
to analyze published studies regarding aPL positivity in infertile
women, the association of aPL and in vitro fertilization (IVF)
outcome, and the effects of medical treatments on IVF outcome
of aPL positive women (8).
Thirteen of 29 studies (44%) assessing aPL prevalence in infer-
tile women identified in that review reported a higher frequency
compared to control populations. However, most of them investi-
gated non-criteria aPL tests, which do not have current clinical
significance, and only one used aPL cut-off as recommended.
The presence of aPL did not influence the outcome of IVF in
the majority of the studies, similar to a previous published meta-
analysis result (15). Finally, treatment of aPL positive patients
submitted to IVF was not beneficial.
Considering these results, the ObTF concluded that there is no
evidence to support investigation of aPL in patients with infertility
or treatment of aPL positive patients to improve results of IVF,
except for research purposes. These conclusions are in consonance
with recommendations of the American Society for Reproductive
Medicine.
Conclusion
Antiphospholipid antibodies are identified in a significant num-
ber of women with adverse obstetric events, such as recurrent
miscarriages, fetal loss, pre-eclampsia, and PI. High quality sci-
entific data to support these associations, however, are lacking,
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2053
Levy et al. Diagnostic of APS in pregnancy
and future studies should address at least part of these uncer-
tainties. The main limitation reported is the definition of positive
aPL, with only few studies addressing this issue as recommended
by the international classification criteria (1). Standardization
of laboratory criteria and multicenter studies may help improve
quality of following studies.
Investigation and treatment of aPL in a context different to that
recommended by international APS criteria, such as two consec-
utive miscarriages, with low aPL titers or presenting infertility,
should be reserved for research purposes, as current knowledge
is insufficient to justify this conduct in daily practice or even
inclusion in the current criteria.
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